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Exposure to lead is monitored most com-
monly by measuring blood lead levels, and in
the United States the criteria for lead poison-
ing and lead toxicity are based on blood lead
as a standard. However, the biologic residence
time of lead in blood is approximately 36 days
(1), and it is therefore an indicator only of
recent lead exposure. Moreover, the concen-
tration of lead in blood is a composite index
that reflects the equilibrium among current
exogenous exposure, excretory loss, and the
movement of lead between bone and other
deep compartments (endogenous exposure).
The relative contribution to the blood lead
level of each of these sources varies with the
levels of current exposure and body burden.
Lead is stored in the human body pre-
dominantly in calcified tissues; 90–95% of
the total lead burden is contained within
bone in nonoccupationally exposed adults
(2,3). The turnover rate of lead in bone is
slow; quantitative estimates of the character-
istic residence time vary, but there is a con-
sensus that it is on the order of years or even
decades (1,4–6). Throughout childhood and
most of adult life, lead exposure from both
environmental and occupational sources
increases lead concentration within calciﬁed
tissue. Bone lead content thus reflects inte-
grated or cumulative lead exposure (7).
Bone lead can be measured noninva-
sively and in vivo by the technique of 109Cd
photon-induced K-shell energy-dispersive
X-ray fluorescence (XRF) (6,8,9). The
88.034 keV gamma rays emitted by a 109Cd
source are used to excite the lead atoms con-
tained in bone. The lead atoms in the bone
subsequently de-excite and may thereby emit
X rays of energy specific to lead. The lead
X rays are recorded by a radiation detector
and, when compared with calibration data,
yield a measure of the lead content of the
bone. Although the technique delivers a
radiation dose to the subject, the radiation
dose and consequent risk arising from an
XRF bone lead measurement are very small
for all age groups, including children (10).
Three previous reports in the literature
compare 109Cd KXRF to independent chem-
ical measurements of lead in bone in
humans. Somervaille et al. (11) analyzed 30
bone samples and found no evidence of a sta-
tistically signiﬁcant difference between XRF
and atomic absorption spectrometry (AAS).
Hu et al. (12) analyzed eight locations from
three legs and reported a correlation coeffi-
cient of 0.98 between XRF and AAS. Aro et
al. (13), using inductively coupled plasma
mass spectrometry, measured eight cadaver
legs and also reported the agreement with
XRF as correlation coefﬁcients.
Herein we report results of a comparison
between XRF and AAS measurements of the
lead concentration in 44 swine femurs.
Validation of our XRF method using animal
bones interests us because animals that have
undergone controlled dosing with lead may
serve in the future as a source of calibration,
validation, or standard reference materials
for human XRF measurements.
Materials and Methods
All procedures performed on animals fol-
lowed the NIH Guide for the Care and Use
of Laboratory Animals (14), and were
approved by the Institutional Animal Care
and Use Committee of University of
Missouri-Columbia. The femurs measured
for this study came from the University of
Missouri-Columbia study of the uptake and
retention of lead in swine (15). The animals
were dosed with 75, 225, and 675 µg Pb/kg
body weight/day for 15 days with lead-
contaminated soil. 
XRF measurements. XRF was performed
at the mid-shaft of bare left femurs using a
spot source measurement system (8). The
right femurs were destructively analyzed via
AAS before the collaboration started; only
the left femurs remained. The XRF measure-
ment system consisted of a 2,000 mm2
intrinsic germanium detector (Canberra
model GL2020R; Canberra Industries,
Meriden, CT, USA), amplifier (Canberra
model 2024), 450 MHz Wilkinson analog-
to-digital converter (Canberra model 8706),
and multichannel analyzer (Canberra model
S100). The source activity was 0.6 GBq (16
mCi). The ampliﬁer Gaussian shaping time
was 1 µsec, which gave a full-width at half-
maximum (FWHM) of approximately 700
eV for the 88.034 keV peak from elastically
scattered 109Cd γ-rays for both calibration
and bone spectra. Spectra were acquired for
half-hour (true time). 
For the analysis of spectra, a nonpolyno-
mial mathematic function (the model) is ﬁt-
ted to the pulse-height distribution. The
model used consists of one or more expo-
nentials that represent the shape of the spec-
tral background, Gaussian functions that
represent the X-ray peaks, and a step func-
tion under each peak. The parameters of the
mathematic function are then adjusted to
give the best fit, as measured by the χ2 per
degree of freedom. The method of parame-
ter adjustment used is credited to Marquardt
(16). Curve ﬁtting is conducted with a com-
puter program written in Fortran, the
essence of which has been described by
Bevington (17). A second program produces
the concentration of lead in bone and an
estimate of the statistical uncertainty (one
standard deviation) therein via comparison
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lead-acetate–doped plaster-of-paris calibra-
tion standards (9). The calibration standards
ranged in lead concentration from 0 to 163
µg/g plaster-of-paris, equivalent to 238 µg/g
bone mineral (18). The lead concentrations
of the plaster calibration standards were not
verified via a chemical method (e.g., AAS).
We used the lead Kα1 and Kβ1 X-ray peaks
(International Union of Pure and Applied
Chemistry notation K-L3 and K-M3, respec-
tively) to calculate estimates of the femur
lead concentration (Kα1[Pb] and Kβ1[Pb],
respectively), which we then combined
(9,19) into an overall estimate (XRF[Pb]).
The measurement uncertainty, calculated
using these algorithms, is not identical to the
standard deviation of repeated measurements
(20). Nevertheless, the measurement uncer-
tainty is still of interest because it is a mea-
sure of the statistical uncertainty in the
estimate of an individual lead concentration.
The lowest XRF[Pb] recorded was nega-
tive. Kim et al. (21,22) have examined how
negative XRF[Pb] results can be obtained
from measurements of low lead concentra-
tion bones because of XRF measurement
error, and how retention of all the data
“makes better use of the data for a popula-
tion in epidemiologic studies” (22). All
XRF[Pb] were therefore retained for the
present study.
The International Union of Pure and
Applied Chemistry lower limit of detection
(three times the standard deviation of the
predicted concentrations obtained from
repeated measurements of a low-concentra-
tion sample) for measurements of a plaster-
of-paris calibration phantom of nominal
zero lead concentration, acquired over the
course of the femur measurements, was 2.5
µg Pb per gram of plaster [equivalent to 3.6
µg Pb per gram of bone mineral (18)].
Calibration standards of nominal zero
lead concentration showed no evidence of
contamination of the standards themselves
or of the room where bone lead measure-
ments were performed [for a full discussion
of the sources of contamination and how to
correct for them, see Todd (23)].
AAS measurements. AAS measurements
were made on the right femur. Soft tissue
was flensed from the femurs with a knife.
We dried the femurs in an oven for 4 hr
before ashing. Graphite furnace AAS analysis
was performed by a commercial laboratory
(L.E.T. Inc, Columbia, MO), which
received the bone samples in blinded fash-
ion. The lab evaluated AAS detection limit
for each sample and varied between 1 and 2
µg Pb (g ashed bone)–1. 
The commercial laboratory performed
duplicate AAS analyses on a subset of the
samples, all of which were within twice the
sample detection limit. We used spiked sam-
ples to estimate sample recovery at 99.6%
[standard deviation (SD) 10.5%]. We also
ran an analytic check sample of 202 ng/mL,
which was, on average, 100.3% of its certi-
ﬁed value (SD 3.5%). Finally, we ran blank
samples, all of which were < 1 ng/mL.
Statistical Analysis 
We performed statistical analyses with SAS
(SAS Institute Inc., Cary, NC). We exam-
ined box plots of AAS and XRF measure-
ments for symmetry, normality, and any
“extreme” outliers (an observation more
than three interquartile ranges from the 25th
or 75th percentiles). There were no extreme
outliers, so we retained all data and included
them in the results. We used Levene’s test to
assess the homogeneity of variances of the
concentrations (i.e., the squares of the stan-
dard deviations of the results obtained from
the members of a group) within the six tech-
nique × dose groups (i.e., groups of XRF
and AAS concentrations for each of the three
dose groups).
We assessed agreement between XRF and
AAS across dose groups via mixed modeling
(24), which accounted for the correlation
between measurements made within the same
pig. We tested nonlinear associations but
found them not signiﬁcant. We assessed paral-
lelism of the “technique” (i.e., XRF and AAS)
slopes (of lead concentration vs. dose) by test-
ing the hypothesis that the interaction
between technique and dose was equal to zero.
When the interaction between technique and
dose was not significantly different from
zero, we estimated the difference between
XRF and AAS from the model with parallel
slopes (i.e., excluding the technique × dose
interaction term). 
To compare our data with those
reported in the literature, we performed
other analyses (which are less pertinent to
measuring agreement): ordinary least squares
unweighted regression between XRF and
AAS, Pearson and Spearman (rank) correla-
tion coefﬁcients, and paired t-tests. 
Results
The units of XRF results (µg of lead per
gram of bone mineral) and AAS results (µg
of lead per gram of ashed bone) are assumed
to be identical; µg/g is therefore used for
both hereafter. 
The number of swine femurs measured
from lead dose groups of 75, 225, and 675
µg/kg/day were 14, 15, and 15, respectively.
Descriptive statistics for XRF[Pb] and AAS-
measured femur lead concentrations
(AAS[Pb]) are shown in Table 1. We com-
pared AAS[Pb] to both the individual esti-
mates of lead concentration given by
Kα1[Pb] and Kβ1[Pb] and to the overall esti-
mate, XRF[Pb]. The results of this analysis
are shown in Table 2.
For each of the three XRF and AAS
comparisons, the variances of the concentra-
tions within the six technique × dose groups
(two techniques in each of three dose
groups) were not homogeneous (Levene’s p-
value < 0.012), but they were normally
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Table 1. Descriptive statistics of 44 swine femur lead concentrations made via both XRF and AAS.
Lead dose Mean SD Minimum Median Maximum
Method (µg/kg/day) No. (µg/g) (µg/g) (µg/g) (µg/g) (µg/g)
AAS[Pb] All 44 7.6 6.3 1.0 6.0 24.5
XRF[Pb] All 44 10.2 6.2 –2.5 10.2 25.9
AAS[Pb] 75 14 2.0 0.6 1.0 2.2 2.8
XRF[Pb] 75 14 5.1 4.9 –2.5 4.4 12.0
AAS[Pb] 225 15 5.5 1.5 3.0 6.0 8.0
XRF[Pb] 225 15 9.6 4.1 5.2 8.8 18.8
AAS[Pb] 675 15 14.9 5.3 7.0 14.5 24.5
XRF[Pb] 675 15 15.4 4.7 7.1 15.1 25.9
Table 2. Mixed modeling analysis of estimates of femur lead concentration and lead dose. 
Model Estimate (SE) p-Value
Comparing AAS[Pb] to Kα1[Pb]
Intercept (µg/g) 1.5575 (1.1753) 0.1923
Dose (µg/g per µg/kg/day) 0.0171 (0.0028) < 0.0001
Technique (µg/g) –0.9842 (1.4910) 0.5128
Technique × dose (µg/g per µg/kg/day) 0.0041 (0.0036) 0.2562
Comparing AAS[Pb] to Kβ1[Pb]
Intercept (µg/g) 8.1048 (1.0797) < 0.0001
Dose (µg/g per µg/kg/day) 0.0149 (0.0026) < 0.0001
Technique (µg/g) –7.5315 (1.3681) < 0.0001
Technique × dose (µg/g per µg/kg/day) 0.0063 (0.0033) 0.0602
Comparing AAS[Pb] to XRF[Pb]
Intercept (µg/g) 4.8116 (0.9778) < 0.0001
Dose (µg/g per µg/kg/day) 0.0162 (0.0023) < 0.0001
Technique (µg/g) –4.2383 (1.1841) 0.0009 
Technique × dose (µg/g per µg/kg/day) 0.0051 (0.0028) 0.0807distributed (Kolmogorov-Smirnov p-value 
> 0.10). The inhomogeneity of the variances
was reduced but not removed by a natural
logarithm transformation of the data, but
there was no difference between the conclu-
sions drawn from the transformed and
untransformed data. The analyses of the
untransformed data are presented for all
aspects of the study both for ease of interpre-
tation and because mixed modeling is mod-
erately robust against unequal variances.
When Kα1[Pb] is compared to AAS[Pb],
mixed modeling (for which there were no
influential observations) showed that dose
was a significant factor, but that neither
technique nor technique × dose was signiﬁ-
cant. The nonsigniﬁcance of technique and
technique × dose indicates that the relation-
ship between lead concentration (measured
by Kα1[Pb] and AAS[Pb]) and dose did not
differ for the two techniques with regard to
either the origins and the rates of change:
The concentration-versus-dose lines were
coincident; their slopes and intercepts were
not signiﬁcantly different. For AAS[Pb], the
relation was: 
AAS[Pb] = 0.5733 (± 1.1753; p = 0.6282) 
+ [0.0212 (± 0.0028; p < 0.0001) × dose].
For Kα1[Pb], the relation was:
Kα1[Pb] = 1.5575 (± 1.1753; p = 0.1923) 
+ [0.0171 (± 0.0028; p < 0.0001) × dose].
The difference between predicted AAS[Pb]
and Kα1[Pb] was 0.37 µg/g [SE 0.91 µg/g;
p-value 0.68; 95% confidence limits (CL)
–1.47 to 2.22 µg/g].
When comparing Kβ1[Pb] and AAS[Pb],
mixed modeling (for which there were no
influential observations) showed that dose
and technique were both significant factors
and that technique × dose was also of bor-
derline signiﬁcance (p = 0.06). The marginal
significance of technique × dose indicates
that the relationships between lead concen-
tration and dose were different for the two
techniques: The concentration-versus-dose
lines had slopes and intercepts that were sig-
nificantly different. The relation for
AAS[Pb] is given above. The relation for
Kβ1[Pb] was:
Kβ1[Pb] = 8.1048 (± 1.0797; p < 0.0001) 
+ [0.0149 (± 0.0026; p < 0.0001) × dose].
There was, therefore, a statistically signifi-
cant difference between the lead concentra-
tions obtained by the two techniques in each
of the three dose groups. Kβ1[Pb] consis-
tently overestimated AAS[Pb], but the differ-
ence between predicted Kβ1[Pb] and
AAS[Pb] decreased as the dose increased. For
the 75 µg/kg/day dose group, the difference
between predicted AAS[Pb] and Kβ1[Pb]
was –7.1 µg/g (SE 1.2 µg/g; p < 0.0001;
95% CL, –9.44 to –4.67 µg/g); for the 225
µg/kg/day dose group, the difference was
–6.11 µg/g (SE 0.90 µg/g; p < 0.0001; 95%
CL, –7.93 to –4.28 µg/g); and for the 675
µg/kg/day dose group, the difference was
–3.26 µg/g (SE 1.40 µg/g; p = 0.0252; 95%
CL, –6.09 to –0.43 µg/g). The difference
between predicted AAS[Pb] and Kβ1[Pb] at
the mean dose of 330.7 µg/kg/day was –5.4
µg/g (SE 0.84 µg/g; p < 0.0001; 95% CL,
–7.12 to –3.75 µg/g). 
The situation for XRF[Pb] (the single
estimate of lead concentration obtained by
combining Kα1[Pb] and Kβ1[Pb]) was inter-
mediate between those for Kα1[Pb] and
Kβ1[Pb], as expected. When comparing
XRF[Pb] to AAS[Pb], mixed modeling (for
which there were no inﬂuential observations)
showed that both dose and technique were
signiﬁcant factors and that technique × dose
was of borderline significance (p = 0.08).
Again, the marginal significance of tech-
nique × dose indicates that the relationships
between lead concentration and dose dif-
fered for the two techniques: The lines had
slopes and intercepts that were signiﬁcantly
different. The relation for AAS[Pb] is given
above. The relation for XRF[Pb] was: 
XRF[Pb] = 4.8116 (± 0.9778; p < 0.0001) 
+ [0.0162 (± 0.0023; p < 0.0001) × dose].
There was a statistically signiﬁcant differ-
ence between the lead concentrations
obtained by the two techniques in both the
75 µg/kg/day and 225 µg/kg/day dose
groups, but no significant difference in the
675 µg/kg/day dose group. XRF[Pb] consis-
tently overestimated AAS[Pb], but the differ-
ence between the two techniques decreased
as dose increased. For the 75 µg/kg/day dose
group, the difference between predicted
AAS[Pb] and XRF[Pb] was –3.86 µg/g (SE
1.02 µg/g; p = 0.0005; 95% CL, –5.92 to
–1.79 µg/g); for the 225 µg/kg/day dose
group, the difference was –3.10 µg/g (SE
0.78 µg/g; p = 0.0003; 95% CL, –4.68 to
–1.52 µg/g); and for the 675 µg/kg/day dose
group, the difference was –0.81 µg/g (SE
1.21 µg/g; p = 0.5070; 95% CL, –3.26 to
–1.64 µg/g). The difference between pre-
dicted AAS[Pb] and XRF[Pb] at the mean
dose of 330.7 µg/kg/day was –2.56 µg/g (SE
0.72 µg/g; p = 0.0010; 95% CL, –4.02 to
–1.10 µg/g). 
The results of regression analysis and the
correlation coefficients, performed to allow
comparison to the published literature, are
shown in Table 3. Paired t-tests showed a) no
significant difference between predicted
Kα1[Pb] and AAS[Pb] in any of the three
lead dose groups or in the data from all three
lead dose groups combined; b) a signiﬁcant
difference between predicted Kβ1[Pb] and
AAS[Pb] in all three lead dose groups
(although the difference in the 675
µg/kg/day dose group was of borderline sig-
niﬁcance; p = 0.0465) and in the data from
all three lead dose groups combined; and c) a
significant difference between predicted
XRF[Pb] and AAS[Pb] in the 75 µg/kg/day
and 225 µg/kg/day dose groups; no signifi-
cant difference in the 675 µg/kg/day dose
group; and a signiﬁcant difference in the data
from all three lead dose groups combined.
Discussion
In our analysis of agreement, AAS is consid-
ered to be the reference method, but agree-
ment between XRF and AAS does not
preclude, of course, the presence of a system-
atic bias in each of the techniques.
Qualitatively, the agreement between
Kα1[Pb] and AAS[Pb] appears to be good, but
the agreement between Kβ1[Pb] and AAS[Pb]
is not. There are several possible reasons for
this. For example, Somervaille et al. (11), in
measurements of human tibiae, found no evi-
dence that random differences between the
two techniques were greater than could be
accounted for by the measurement variance of
each technique; but they noted that any inho-
mogeneity in lead concentration may con-
tribute unaccounted-for random error. Such
inhomogeneity may also account partly for the
differences between XRF and AAS in our
measurements. So, too, may the fact that AAS
was performed on the right femur whereas
XRF was performed on the left femur.
However, we do not expect this difference to
be important, because a previous study (4) has
shown no difference between measurements of
left and right human tibiae with the limits of
precision of those authors’ AAS method. 
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Table 3. Ordinary least squares (unweighted) regression and correlation coefficients between XRF-
measured and AAS-measured lead concentration in 44 swine femurs.
p-Value for 
Dependent Independent Intercept (± SE) Slope (± SE) testing Spearman rank r
variable variable (p-Value) (p-Value) Ho:slope = 1 Pearson r (p-Value)
Kα1[Pb] AAS[Pb] 1.8 (± 1.4) 0.71 (± 0.14) 0.0474 0.6149 0.5815
(0.2)( < 0.0001)( < 0.0001)
Kβ1[Pb] AAS[Pb] 8.3 (± 1.2) 0.62 (± 0.13) 0.0042 0.6028 0.5855
(< 0.001)( < 0.0001)( < 0.0001)
XRF[Pb] AAS[Pb] 5.1 (± 1.1) 0.67 (± 0.11) 0.0043 0.6904 0.6612
(< 0.001)( < 0.0001)( < 0.0001)We believe it most likely that the reason
for the discrepancy in Kβ1[Pb] is technical
rather than biologic: namely, the X-ray peak
area extraction program parameter for a cal-
cium/phosphorous-related spectrum feature
(the amplitude, as a fraction of the coherent
scatter peak, of the discontinuity in the dis-
tribution of photon counts arising from
Compton scattering off tightly bound elec-
trons from calcium and phosphorous). It is
possible that the value used for this fitting
parameter is not optimal for measurements
of swine femur. The parameter is treated as a
constant, although it is calculated using
assumed compositions of human bone. Any
difference between the composition of
human and swine bone would affect the cal-
culated value of this parameter. There were
too few data to show a clear minimum in the
sum of the squares of the differences
between Kβ1[Pb] and AAS[Pb] when we
manually adjusted the ﬁtting parameter; we
therefore had insufﬁcient grounds for deter-
mining whether an incorrect value for this
parameter was partially or wholly responsible
for the bias between Kβ1[Pb] and AAS[Pb].
To use XRF as a substitute for AAS measure-
ments of swine femur, only Kα1[Pb] would
be used until the bias between Kβ1[Pb] and
AAS[Pb] is explained and corrected. 
The SD of repeated XRF measurements of
the swine femur was greater than that
obtained from repeated measurements of
human bones (data not shown), a result of the
smaller size of the swine femurs. Our quantita-
tive estimates of the conﬁdence limits for the
agreement between XRF and AAS probably
overestimate (i.e., are wider than) the conﬁ-
dence limits that would be obtained from a
comparison between XRF and AAS per-
formed on human bones. Nevertheless, we can
compare our data to those of previous reports.
One previous study compared a substan-
tial number (80) of XRF and AAS measure-
ments from 30 human bone samples that
underwent both AAS and XRF analysis (11).
In that study, Somervaille et al. measured
human bone samples (mainly tibiae) and cal-
culated the mean difference and the SD of
the differences. From these, they calculated
the t statistic and the probability (90%) that
there was no difference between the two sets
of measurements. Not all the data used to
calculate these statistics were from indepen-
dent samples, and we therefore recalculated
them from the data presented by Somervaille
et al. (11): XRF[Pb] underestimated
AAS[Pb] by 0.63 µg/g, and the SD of the
differences was 6.79 µg/g. The mean differ-
ence in our study (XRF[Pb] overestimated
AAS[Pb] by 2.6 µg/g) was signiﬁcantly (p =
0.0218) worse than that reported by
Somervaille et al. (11). The SD of the differ-
ences in our study (4.9 µg/g) was less than
that calculated from the data of Somervaille
et al. (11), but the difference was of border-
line signiﬁcance (p = 0.044). 
Somervaille et al. (11) also calculated χ2
and found that the uncertainties associated
with XRF and AAS were consistent with the
SD of the differences between the two tech-
niques. This calculation requires, for several
stages of the AAS measurement process,
knowledge of the measurement uncertainty
that was unavailable to us. However,
Somervaille et al. (11) assigned a ± 10%
uncertainty to all the AAS data. We there-
fore calculated χ2 for our data for three AAS
measurement uncertainty levels: ± 10% per
Somervaille et al. (11); ± 1 µg/g (the detec-
tion limit); and ± 1/2 µg/g (half the detec-
tion limit). All χ2 tests were failed (regardless
of the level of uncertainty assigned to the
AAS data and regardless of whether the
entire data set or an individual concentration
group was considered), indicating that the
SD of our differences between XRF[Pb] and
AAS[Pb] was not consistent with the uncer-
tainties assigned to each technique. For com-
pleteness, we note that Somervaille et al.
(11) found no significant linear trend in
their differences between XRF[Pb] and
AAS[Pb], and we found no nonlinear trend.
Hu et al. (12) performed XRF and AAS
at eight locations on three human legs. The
agreement between XRF and AAS was given
as a correlation coefficient (0.98), a slope
(1.02, uncertainty not given), and an inter-
cept (–1 µg/g, uncertainty not given). Our
swine femur data showed a lower Pearson
correlation coefficient, a slope that was sig-
niﬁcantly different from unity (suggesting a
proportional bias), and an intercept that was
signiﬁcantly different from zero (suggesting a
ﬁxed bias).
Aro et al. (13) measured tibia and patella
lead concentrations via both 109Cd-based
KXRF and inductively coupled plasma mass
spectrometry (ICPMS) in eight amputated
cadaver legs. The authors quote only correla-
tion coefﬁcients but present their data allow-
ing the mean and standard deviation of the
differences between XRF and ICPMS to be
calculated along with the limits of agree-
ment. The data of Aro et al. (13) yield a
mean (± SD) difference of –0.7 (± 2.7) µg/g
and –1.2 (± 1.8) µg/g for intact tibiae and
patellae respectively. The sign of each mean
difference indicates that XRF underesti-
mated the bone lead concentration obtained
by ICPMS. The mean difference between
XRF[Pb] and AAS[Pb] in the swine femur
was not quite significantly worse (greater)
than the mean difference between the XRF
and ICPMS tibia measurements of Aro et al.
(13) (p = 0.076). There was no more vari-
ability in the differences between XRF[Pb]
and AAS[Pb] in our study of swine femurs
than in the human tibia data of Aro et al.
(13), but the difference was also of border-
line signiﬁcance (p = 0.0997).
Conclusion
The agreement (i.e., the mean difference)
between XRF and AAS measurement of
swine femur lead concentrations is similar to
but worse than the agreements reported
between XRF and AAS measurements of
human tibiae. Swine bones may require
adjustment of the XRF spectrum Kβ1 peak
extraction method. The findings of this
study are applicable only to measurements of
swine femurs using our method for 109Cd-
based KXRF and may not necessarily extend
to the technique in general.
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